BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35724920)

  • 21. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical applications of 3-dimensional printing in radiation therapy.
    Zhao Y; Moran K; Yewondwossen M; Allan J; Clarke S; Rajaraman M; Wilke D; Joseph P; Robar JL
    Med Dosim; 2017 Summer; 42(2):150-155. PubMed ID: 28495033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization and experimental characterization of the innovative thermo-brachytherapy seed for prostate cancer treatment.
    Taghizadeh S; Shvydka D; Shan A; Mian OY; Parsai EI
    Med Phys; 2024 Feb; 51(2):839-853. PubMed ID: 38159297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy.
    Thomas MD; Cormack R; Tempany CM; Kumar S; Manola J; Schneider L; Hurwitz MD; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):905-8. PubMed ID: 10863058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determining optimal eluter design by modeling physical dose enhancement in brachytherapy.
    Guthier CV; D'Amico AV; King MT; Nguyen PL; Orio PF; Sridhar S; Makrigiorgos GM; Cormack RA
    Med Phys; 2018 Jun; ():. PubMed ID: 29905964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosimetric influence of seed spacers and end-weld thickness for permanent prostate brachytherapy.
    Melhus CS; Mikell JK; Frank SJ; Mourtada F; Rivard MJ
    Brachytherapy; 2014; 13(3):304-10. PubMed ID: 24139289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
    Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
    Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention.
    Sacco DE; Daller M; Grocela JA; Babayan RK; Zietman AL
    BJU Int; 2003 Mar; 91(4):345-9. PubMed ID: 12603412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3D localization of implanted radioactive sources in the prostate using trans-urethral ultrasound.
    Holmes DR; Davis BJ; Robb RA
    Stud Health Technol Inform; 2001; 81():199-205. PubMed ID: 11317739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy.
    Tsui G; Gillan C; Pond G; Catton C; Crook J
    Cancer J; 2005; 11(2):122-32. PubMed ID: 15969987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen.
    Kukiełka AM; Dąbrowski T; Walasek T; Olchawa A; Kudzia R; Dybek D
    Brachytherapy; 2015; 14(3):359-65. PubMed ID: 25736733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E-jet 3D printed drug delivery implants to inhibit growth and metastasis of orthotopic breast cancer.
    Yang Y; Qiao X; Huang R; Chen H; Shi X; Wang J; Tan W; Tan Z
    Biomaterials; 2020 Feb; 230():119618. PubMed ID: 31757530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.
    Schutzer ME; Orio PF; Biagioli MC; Asher DA; Lomas H; Moghanaki D
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):96-103. PubMed ID: 25687401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of transitioning of planning techniques in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer from two- to three-dimensional planning.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Brachytherapy; 2019; 18(5):589-597. PubMed ID: 31229363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.